Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Live Interviews Editor's pick

Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners

"85% of failures are us having failed the molecule, not the molecule having not delivered."

Dr. Adil Ali
Published
1 min read

In the chaos of Jefferies Healthcare Conference, I caught up with Ali Pashazadeh, CEO of Treehill Partners - a specialist advisory firm transforming the life sciences - to find out why:

  • 50% of Phase III drugs fail (and how 75% of those failures could be avoided)
  • Biotech execs think in verticals, when they should be thinking horizontally
  • We don't see IPOs from British biotechs

Please sign-up to continue reading

Subscribe

Be the first to receive exclusive interviews with cutting-edge biotech and pharma CEOs, straight to your inbox. Unsubscribe at any time. Already have an account? Sign In

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

More Live Interviews ↗